Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 12, 2007

CombinatoRx Pockets $7M with Extension of Drug Device Partnership with Angiotech

  • CombinatoRx and Angiotech Pharmaceuticals have doubled the term of their R&D collaboration related to drug device and local medicines. Based on the successful advancement of a number of product candidates in preclinical models, the extended partnership to a total of five years has resulted in a $7-million payment to CombinatoRx due before October 3, 2007.

    In October 2005, the companies entered into a research and license agreement that granted Angiotech an option to evaluate and exclusively license compounds it selected from the CombinatoRx clinical and preclinical pipeline and its bioinformatics database of synergistic combination pharmaceuticals.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »